1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>Canada

In Brief

Health Canada warns of benzocaine risk; Perrigo first with store-brand Mucinex; NAD enters Glaxo/Colgate toothpaste war; Sun Capital snags supplement manufacturer CornerStone; more news In Brief.

Health Canada asks the makers of products with benzocaine, a pain reliever for teething, canker sores and oral irritation, to add to labels risk statements about methemoglobinemia. The rare but serious blood condition is a reaction to the ingredient that can cause confusion and headaches and complicate breathing. The new statements warn consumers to use the smallest amount possible, when to discontinue use and to use with caution in children, among other warnings. The move comes after FDA warned last April that the ingredient can reduce the amount of oxygen carried in the blood. FDA said at the time children under 2 years should not use the ingredient unless under a health care provider’s supervision Also see "FDA Warns Of Deadly Benzocaine Risks, Label Changes Might Be On The Way" - Pink Sheet, 11 April, 2011.. In response, Church & Dwight Co. Inc. reformulated Baby Orajel Naturals without the ingredient Also see "C&D’s Naturals Could Help Retain Orajel Customers After Benzocaine Warning" - Pink Sheet, 12 September, 2011..

Perrigo Co. PLC reaches market first with a store-brand version of Mucinex (guaifenesin) 600-mg tablets, noting April 12 it...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Canada

Here At Last: Canada’s Long-Contested Guidelines For Curbing Excessive Drug Prices

 
• By Neena Brizmohun

Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.

Canada Joins Global Push To Drop Costly Clinical Trials For Biosimilars

 
• By Neena Brizmohun

Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach.

Canada’s HTA Agency Reveals How To Submit AI-Driven Evidence

 
• By Neena Brizmohun

Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.

More from North America

Otsuka/Lundbeck’s Rexulti PTSD Claim Will Test US FDA AdComm’s Supportive Evidence Flexibility

 
• By Bridget Silverman

Rexulti’s post-traumatic stress disorder sNDA tries to make up for a failed Phase III study by placing a Phase II study into a key evidentiary role, raising questions for the July 18 advisory committee meeting about assessing discordant results and post-hoc analyses.

Organ-On-A-Chip: Upcoming US FDA Guidance Could Help Flesh Out ‘Roadmap’

 
• By Michael McCaughan

The FDA is pushing the use of novel alternatives to animal models, but the Government Accountability Office said sponsors need more clarity and hopes an upcoming guidance will help.

Access Risks Loom For All Drugmakers With Fourth Circuit Mifepristone Decision

 
• By Sarah Karlin-Smith

The FDA law establishing REMS authority does not preempt a West Virginia law that would restrict mifepristone use in the state, an appeals court said, a decision that could have broader ramifications for the agency’s authority to ensure drug access.